Suicide in schizophrenia: Risk factors and clozapine treatment

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 3, 1998, Pages 15-20

  Meltzer, Herbert Y ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE;

AGRANULOCYTOSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE; SUICIDE; SUICIDE ATTEMPT; TARDIVE DYSKINESIA;

EID: 0031967082     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Moscicki EK. Identification of suicide risk factors using epidemiologic studies. Psychiatr Clin North Am 1997;20:499-517
2. Tsuang MT, Woolson RF. Excess mortality in schizophrenia and affective disorders. Arch Gen Psychiatry 1978;35:1181-1185
3. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997;8:671-677
4. Planasky K, Johnston R. The occurrence and characteristics of suicidal preoccupation and acts in schizophrenia. Acta Psychiatr Scand 1971;47: 473-483
5. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190
6. Drake RE, Gates C, Colton PG, et al. Suicide among schizophrenics: who is at risk? J Nerv Ment Dis 1984;172:613-617
7. Caldwell CB, Gottesman II. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 1990;16:571-589
8. Caldwell CB, Gottesman II. Schizophrenia: a high-risk factor for suicide: clues to risk reduction. Suicide Life Threat Behav 1992;22:479-493
9. Roy A. Suicide in schizophrenia. Int Rev Psychiatry 1992;4:205-209
10. Meltzer HY, Fatemi H. Suicide in schizophrenia: the effect of clozapine. Clin Neuropharmacol 1995;18(suppl 3):S18-S24
11. Rossau CD, Mortensen PB. Risk factors for suicide in patients with schizophrenia: nested case-control study. BrJ Psychiatry 1997;171:355-359
12. Modestin J, Hoffman H. Completed suicide in psychiatric inpatients and former inpatients. Acta Psychiatr Scand 1989;79:229-234
13. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993;163:183-189
14. Jones JS, Stein DJ, Stanley B, et al. Negative and depressive symptoms in suicidal schizophrenics. Acta Psychiatr Scand 1994;89:81-87
15. Westermeyer JF, Harrow M, Marengo JT. Risk for suicide in schizophrenia and other psychotic and nonpsychotic disorders. J Nerv Ment Dis 1991; 179:259-266
16. Dassori AM, Mezzich JE, Keshavan M. Suicidal indicators in schizophrenia. Acta Psychiatr Scand 1990;81:409-413
17. Bartels SJ, Drake RE, McHugo GJ. Alcohol abuse, depression, and suicidal behavior in schizophrenia. Am J Psychiatry 1992;149:394-395
18. Cohen S, Lavelle J, Rich CL, et al. Rates and correlates of suicide attempts in first-admission psychotic patients. Acta Psychiatr Scand 1994;90: 167-171
19. Roy A. Suicide in chronic schizophrenia. Br J Psychiatry 1992;141: 171-177
20. Amador XF, Harkanz Friedman J, Kasapis C, et al. Suicidal behavior in schizophrenia and its relationship to awareness of illness. Am J Psychiatry 1996;153:1185-1188
21. Proulx F, Lesage AD, Grunberg F. One hundred in-patient suicides. Br J Psychiatry 1997;171:247-250
22. Heilä H, Isometsä ET, Henriksson MM, et al. Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry 1997;154:1235-1242
23. Voruganti LNP, Heslegrave RJ, Awad AG. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nerv Ment Dis 1997;185:463-465
24. Mortensen PB. Suicide among schizophrenic patients: occurrence and risk factors. Clin Neuropharmacol 1995;18(suppl 3):S1-S8
25. Taiminen TJ, Kujari H. Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. Acta Psychiatr Scand 1994;90: 247-251
26. Fenton WS, Maglashen TH, Victor BJ, et al. Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 1997;154:199-204
27. Verkes RJ, Kerkhof GA, Beld E, et al. Suicidality, circadian activity rhythms and platelet serotonergic measures in patients with recurrent suicidal behavior. Acta Psychiatr Scand 1996;93:27-34
28. Young CR, Longhurst JG, Bowers MB Jr, et al. The expanding indications for clozapine. Exp Clin Psychopharmacol 1997;5:216-234
29. Banov MD, Zarate CA Jr, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994;55:295-300
30. Parsa MA, Ramirez LF, Loula EC, et al. Effect of clozapine on psychotic depression and parkinsonism [letter]. J Clin Psychopharmacol 1991;11: 330-331
31. Stahl SM. Essential Psychopharmacology. Cambridge, England: Cambridge University Press: 1996
32. Cohen LJ, Test MA, Brown RL. Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry 1990;147: 602-607
33. Buckley P, Bartell J, Donenwirth K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995;23:607-611
34. Cohen SA, Underwood MT. The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatry 1994;55:440-444
35. Apter A, Gothelf D, Orbach I, et al. Correlation of suicidal and violent behavior in different diagnostic categories in hospitalized adolescent patients. J Am Acad Child Adolesc Psychiatry 1995;34:912-918
36. Yarden P. Observations on suicide in chronic schizophrenics. Compr Psychiatry 1974;15:325-333
37. Beratis S, Lekka NP, Gabriel J. Smoking among suicide attempters. Compr Psychiatry 1997;38(2):74-79
38. Buckley P, Thompson PA, Way L, et al. Substance abuse and clozapine treatment. J Clin Psychiatry 1994;55(9, suppl B):114-116
39. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine [letter]. Am J Psychiatry 1995;152:959
40. Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 1996;47:52-56
41. Fuchs AM. Clozaril: saving lives [letter]. Biol Psychiatry 1994;36:350
42. Wyatt RJ, Henter I, Leary MC, et al. An economic evaluation of schizophrenia - 1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:196-205
43. Revicki DA, Luce BR, Weschler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital and Community Psychiatry 1990;41:850-854
44. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hospital and Community Psychiatry 1994;45: 261-264
45. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992; 160(suppl 17):46-53
46. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hospital and Community Psychiatry 1990;41:882-885
47. Harkavy-Friedman JM, Nelson E. Management of the suicidal patient with schizophrenia. Psychiatr Clin North Am 1997;120:625-640